LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.

Publication

Author(s):

Technau KG, Lazarus E, Kuhn L, Abrams EJ, Sorour G, Strehlau R, Reubenson G, Davies MA, Coovadia A.

Pub Title:

Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.

Pub Date:

Aug 31 2013

Pub Region(s):

Southern Africa

Journal:

Title: 
Pediatr Infect Dis J
Link: 
http://ovidsp.tx.ovid.com/sp-3.12.0b/ovidweb.cgi?QS2=434f4e1a73d37e8c740ce3cde7a337851b409fc97e079cedb8f45b8b367c165abed394f33da4ca744c2e5650cac2852e6ef10e4eecde0ee415161cc42edd05304658c81ed10b979bfb5a6c8239c7a153aad11a3f2d6b3d33c7553853dcf543ced3597628ca

PubMed: 23860481
Pub PDF: PDF icon 23860481.pdf

Abstract

BACKGROUND: Concerns about stavudine (d4T) toxicity have led to increased use of abacavir (ABC) in first-line pediatric antiretroviral treatment (ART) regimens. Field experience with ABC in ART-naïve children is limited.

METHODS: Deidentified demographic, clinical and laboratory data on HIV-infected children initiating ART between 2004 and 2011 in a large pediatric HIV treatment program in Johannesburg, South Africa, were used to compare viral suppression at 6 and 12 months by initial treatment regimen, time to suppression (<400 copies/mL) and rebound (>1000 copies/mL after initial suppression). Adjusted logistic regression was used to investigate confounders and calendar effects.

RESULTS: Two thousand thirty-six children initiated either d4T/3TC- or ABC/3TC-based first-line regimens in combination with either boosted lopinavir (LPV/r) or efavirenz (EFV). 1634 received d4T regimens (LPV/r n = 672; EFV n = 962) and 402 ABC regimens (LPV/r n = 192; EFV n = 210). At 6 and 12 months on ART, viral suppression rate was poorer in ABC versus d4T groups within both the LPV/r and EFV groups (P < 0.0001 for all points). In ABC groups, time to suppression was significantly slower (log-rank P < 0.0001 and P = 0.0092 for LPV/r- and EFV-based, respectively) and time to rebound after suppression significantly faster (log-rank P = 0.014 and P = 0.0001 for LPV/r- and EFV-based, respectively). Logistic regression confirmed the worse outcomes in the ABC groups even after adjustment for confounders.

CONCLUSION: Data from this urban pediatric ART service program show significantly poorer virological performance of ABC compared with d4T-based regimens, a signal that urgently warrants further investigation.

The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

Technau KG, Lazarus E, Kuhn L, Abrams EJ, Sorour G, Strehlau R, Reubenson G, Davies MA, Coovadia A. Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children. Pediatr Infect Dis J. 2013 Aug;32(8):851-5. doi: 10.1097/INF.0b013e31828c3738. PubMed PMID: 23860481; PubMed Central PMCID: PMC3717192.